Thank you, Mr. Chair.
I'll be very brief, and then if there's time my colleague Mr. Thibault may have a question.
I want to ask the witnesses about the notion that Health Canada seems to be proposing to do not only what it already does in terms of the pre-market approval of drugs, but also to do the post-market surveillance of drugs. To what degree do you see a conflict of interest in doing that? What problems do you foresee because of it? Do you think this process of post-market surveillance should be at arm's length, and how would you achieve that?
Mr. Cassels is keen to answer.